I am a
Home I AM A Search Login

Papers of the Week


Papers: 17 Oct 2020 - 23 Oct 2020


Animal Studies, Pharmacology/Drug Development


2020 Oct 19


ACS Chem Neurosci

(E)-3-Furan-2-yl—tolyl-acrylamide and its Derivative DM489 Decrease Neuropathic Pain in Mice Predominantly by α7 Nicotinic Acetylcholine Receptor Potentiation.

Authors

Arias HR, Ghelardini C, Lucarini E, Tae H-S, Yousuf A, Marcovich I, Manetti D, Romanelli M N, Elgoyhen A B, Adams DJ, Di Cesare Mannelli L
ACS Chem Neurosci. 2020 Oct 19.
PMID: 33073974.

Abstract

The main objective of this study was to determine whether ()-3-furan-2-yl—tolyl-acrylamide (PAM-2) and its structural derivative DM489 produce anti-neuropathic pain activity using the streptozotocin (STZ)- and oxaliplatin-induced neuropathic pain animal models. To assess possible mechanisms of action, the pharmacological activity of these compounds was determined at α7 and α9α10 nicotinic acetylcholine receptors (nAChRs) and Ca2.2 channels expressed alone or coexpressed with G protein-coupled GABA receptors. The animal results indicated that a single dose of 3 mg/kg PAM-2 or DM489 decreases STZ-induced neuropathic pain in mice, and chemotherapy-induced neuropathic pain is decreased by PAM-2 (3 mg/kg) and DM489 (10 mg/kg). The observed anti-neuropathic pain activity was inhibited by the α7-selective antagonist methyllycaconitine. The coadministration of oxaliplatin with an inactive dose (1 mg/kg) of PAM-2 decreased the development of neuropathic pain after 14, but not 7, days of cotreatment. The electrophysiological results indicated that PAM-2 potentiates human (h) and rat (r) α7 nAChRs with 2-7 times higher potency than that for hCa2.2 channel inhibition and an even greater difference compared to that for rα9α10 nAChR inhibition. These results support the notion that α7 nAChR potentiation is likely the predominant molecular mechanism underlying the observed anti-nociceptive pain activity of these compounds.